A Phase II Trial of Single-agent Cetuximab Dose Escalated to Rash in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

Study start date: November 1, 2004

Inclusion Criteria: * subjects must have recurrent or persistent epithelial ovarian or primary peritoneal carcinoma. Histologic confirmation of the original primary tumor is required. * EGFR expression must be positive as determined by an outside reference lab * Subjects must have had a treatment-free interval following platinum of \<12 mos * All subjects must have measurable disease at baseline * Subjects must have at least one recurrent lesion to be used to assess response * Recovery from effect of recent surgery, radiotherapy or chemotherapy Exclusion Criteria: * Subjects with other invasive malignancies (including peritoneal mesotheliomas) * Subjects with unstable cardiac disease or MI within 6 mos * Subjects with Acute hepatitis * Subjects with active or uncontrolled infection * A history of prior cetuximab or other therapy which targets the EGFR pathway or prior history of prior chimerized or murine monoclonal antibody therapy